pyrazines has been researched along with Minimal Disease, Residual in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Armand, P; Arnason, JE; Brown, JR; Crombie, JL; Davids, MS; Fisher, DC; Jacobson, CA; Kim, AI; LaCasce, AS; Lampson, BL; Lowney, JC; Montegaard, J; Ng, SY; Patterson, V; Pazienza, S; Tyekucheva, S; Wang, Z; Weinstock, M | 1 |
| Brüggemann, M; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Franzen, F; Fürstenau, M; Giza, A; Hallek, M; Ritgen, M; Robrecht, S; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Weiss, J | 1 |
| Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C | 1 |
| Casasnovas, O; Damaj, G; Davies, A; Doorduijn, JK; Dupuis, J; Długosz-Danecka, M; Eek, R; Frigault, MM; Goy, A; Izumi, R; Jacobsen, E; Jain, P; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Nguyen, D; Oberic, L; Panizo, C; Patel, P; Robak, T; Rule, S; Shah, B; Smith, SD; Wang, M; Yin, M; Zinzani, PL | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Estey, EH; Percival, MM | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M | 1 |
| Imai, K | 1 |
| Nakaseko, C | 1 |
| Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Ferrero, S; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Pagliano, G; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Santo, L | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| Anderson, KC; Ansell, SM; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Joshua, DE; Kastritis, E; Kimby, E; Kyle, RA; Leblond, V; Leleu, X; Merlini, G; Morel, P; Morice, WG; Morra, E; Munshi, NC; Ocio, EM; Owen, RG; Patterson, CJ; Rawstron, AC; Stone, MJ; Tedeschi, A; Terpos, E; Treon, SP | 1 |
4 review(s) available for pyrazines and Minimal Disease, Residual
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
6 trial(s) available for pyrazines and Minimal Disease, Residual
| Article | Year |
|---|---|
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boston; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Pyrazines; Remission Induction; Sulfonamides; Time Factors | 2021 |
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Circulating Tumor DNA; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Pyrazines; Sulfonamides | 2022 |
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides | 2022 |
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pyrazines; Time Factors; Treatment Outcome | 2019 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Recurrence; Survival Analysis; Thalidomide; Transplantation, Autologous | 2015 |
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Tumor Burden | 2010 |
3 other study(ies) available for pyrazines and Minimal Disease, Residual
| Article | Year |
|---|---|
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
Topics: Antibodies, Monoclonal; Antimetabolites; Bone Marrow Examination; Boronic Acids; Bortezomib; Densitometry; Disease Progression; Disease-Free Survival; Forecasting; Hematopoiesis; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunosuppressive Agents; Neoplasm, Residual; Nephelometry and Turbidimetry; Positron-Emission Tomography; Pyrazines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia | 2013 |